Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mafenide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.95 |
| ▸ | CA1 | P00915 | 13/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.95 |
| ▸ | CA9 | Q16790 | 10/20 | 0.91 |
| ▸ | CA12 | O43570 | 9/20 | 0.91 |
| ▸ | CA7 | P43166 | 6/20 | 0.91 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.91 |
| ▸ | CA4 | P22748 | 5/20 | 0.91 |
| ▸ | CA6 | P23280 | 5/20 | 0.91 |
| ▸ | CA5A | P35218 | 5/20 | 0.91 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mafenide SCHEMBL425524 | 0.98 | CA2 (1.00) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL1203324 | 0.98 | CA2 (1.00) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL9295695 | 0.95 | CA2 (1.00) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL41628 | 0.95 | CA2 (1.00) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL27294054 | 0.93 | CA2 (0.87) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL2934434 | 0.91 | CA2 (0.91) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL1072130 | 0.89 | CA2 (0.87) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL11664949 | 0.87 | CA2 (0.83) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL27599824 | 0.85 | KDM4E (0.82) | CA2CA1MAPTCA9CA12 | |
| Mafenide SCHEMBL41627 | 0.84 | SMN1; SMN2 (1.00) | CA2CA1MAPTCA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8754233-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8410272-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | disclosed |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Valocor Therapeutics, Inc. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | disclosed |
| US-7625917-B2 | S-o-(phenylaminocarbonyl)phenyl-substituted, especially with a quaternary onium group; enhanced antiviral activity and better reactivity with zinc finger moieties, particularly, the zinc finger on HIV-1's NCp7 nucleocapsid protein | TURPIN JAMES A | 2009-12-01 | — | — | US | disclosed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
| US-5580689-A | SOLFTENABLE LAYER OF SOFTENABLE MATERIAL, PIGMENT SENSITIVE TO INFRARED OR RED LIGHT ILLUMINATION, AND MIGRATION MARKING MATERIAL | XEROX CORPORATION (US) | 1996-12-03 | — | — | US | disclosed |
| US-5534374-A | Migration imaging members | XEROX CORPORATION (US) | 1996-07-09 | — | — | US | disclosed |
| WO-1996004242-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| US-5476863-A | Inhibitors of platelet activating factor and diseases caused thereby; stability | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5476864-A | Therapy for diseases caused by platelet activation factor | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| EP-0353474-B1 | Glycerin derivative and its pharmacological use | EISAI CO LTD (JP) | 1995-04-05 | — | — | EP | disclosed |
| US-5273985-A | A 1-phenylaminocarbonyl-2-sulfoamidophenyleneamino-3-pyrid-2-ylaminocarbonyl glyceride | EISAI CO., LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| US-5037827-A | Useful for treatment of disease caused by platelet activating factory | EISAI CO., LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0353474-A2 | Glycerin derivative and its pharmacological use | Eisai Co., Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | TST, PTK2, PTK2B | CA2 1900/4885CA1 4436/4885MAPT 4331/4885 |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | REN, PGF, PKD1 | CA2 1878/4885CA1 4853/4885MAPT 4282/4885 |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | CA2 1890/4885CA1 4805/4885MAPT 865/4885 |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | CA2 1890/4885CA1 4805/4885MAPT 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.